文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA PET/CT联合PET/超声引导前列腺活检可诊断既往活检阴性男性的临床显著前列腺癌

68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results.
PubMed 文献 · J Nucl Med · 2020-02-07

本研究纳入31例既往前列腺活检阴性但血清PSA持续升高的患者,在重复活检前行68Ga-PSMA PET/CT,并按miPSMA-ES评分判读为阴性(0-1分)或阳性(2-3分),所有患者接受标准模板系统活检并最多加穿4针PET/超声引导活检。结果显示68Ga-PSMA PET/CT诊断临床显著前列腺癌的灵敏度100.0%、特异度68.4%、阳性预测值66.7%、阴性预测值100.0%、准确率80.6%,且miPSMA-ES 0-1、2、3组的csPCa检出率分别为0%、54.5%、85.7%。

要点

  • 68Ga-PSMA PET/CT诊断csPCa的灵敏度100.0%、特异度68.4%、准确率80.6%。
  • miPSMA-ES 0-1、2、3组csPCa检出率分别为0%、54.5%、85.7%。
  • 基于病灶SUVmax等半定量参数的预测模型可有效预测csPCa。

核心结论

  • 本研究初步证实68Ga-PSMA PET/CT联合PET/超声引导前列腺活检可有效检出csPCa,活检前68Ga-PSMA PET/CT对所研究人群的csPCa具有预测价值。

研究设计与样本

  • 研究纳入31例既往前列腺活检阴性但血清PSA持续升高的患者,活检前先行68Ga-PSMA PET/CT,再行重复前列腺活检。
  • 按所提出的前列腺癌分子影像标准化评价标准,将68Ga-PSMA PET/CT结果判读为阴性(miPSMA-ES 0-1分)或阳性(miPSMA-ES 2-3分)。
  • 所有患者接受标准模板系统活检并最多加穿4针PET/超声引导活检,计算68Ga-PSMA PET/CT的诊断效能并分析miPSMA-ES与PCa检出率的相关性。
  • 采用68Ga-PSMA PET/CT半定量分析参数建立单因素logistic回归模型预测重复前列腺活检结局。

主要发现

  • 患者中位年龄65岁(范围53-81岁),中位PSA水平18.0 ng/mL(范围5.48-49.77 ng/mL)。
  • 31例患者中15例(48.4%)检出PCa,12例(38.7%)为csPCa。
  • 68Ga-PSMA PET/CT诊断csPCa的灵敏度100.0%、特异度68.4%、阳性预测值66.7%、阴性预测值100.0%、准确率80.6%。
  • PCa检出率随miPSMA-ES升高而增加,miPSMA-ES 0-1、2、3组的csPCa检出率分别为0%、54.5%、85.7%。
  • 基于前列腺病灶SUVmax、肿瘤与正常前列腺背景SUVmax比值、肿瘤与正常肝脏背景SUVmax比值的预测模型曲线下面积分别为0.930、0.877、0.956。

关键数值与推荐

  • miPSMA-ES 0-1分判读为68Ga-PSMA PET/CT阴性,2-3分判读为阳性。
  • 68Ga-PSMA PET/CT诊断csPCa的灵敏度100.0%、特异度68.4%、阳性预测值66.7%、阴性预测值100.0%、准确率80.6%。
  • miPSMA-ES 0-1、2、3组的csPCa检出率分别为0%、54.5%、85.7%。
  • 基于前列腺病灶SUVmax、肿瘤与正常前列腺背景SUVmax比值、肿瘤与正常肝脏背景SUVmax比值的预测模型曲线下面积分别为0.930、0.877、0.956。

临床怎么用

  • 原文结论为68Ga-PSMA PET/CT联合PET/超声引导前列腺活检可有效检出csPCa,活检前68Ga-PSMA PET/CT对所研究人群的csPCa具有预测价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to investigate the feasibility and diagnostic efficacy of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT combined with PET/ultrasound-guided biopsy in the diagnosis of prostate cancer (PCa). Methods: In total, 31 patients with a previously negative prostate biopsy but persistent elevated serum prostate-specific antigen (PSA) were imaged with a 68Ga-PSMA PET/CT ligand before undergoing repeat prostate biopsy. On the basis of the proposed Prostate Cancer Molecular Imaging Standardized Evaluation criteria, 68Ga-PSMA PET/CT results were interpreted as negative (molecular-imaging-for-PSMA expression score [miPSMA-ES] of 0-1) or positive (miPSMA-ES of 2-3). All patients underwent standard template systematic biopsy with up to 4 additional PET/ultrasound-guided biopsy cores. The sensitivity, specificity, positive and negative predictive values, and accuracy of 68Ga-PSMA PET/CT were determined. In addition, the correlation between the miPSMA-ES and the detection rate of PCa was also analyzed. Univariate logistic regression models were established using 68Ga-PSMA PET/CT semiquantitative analysis parameters to predict the outcome of repeat prostate biopsy. Results: The median age of patients was 65 y (range, 53-81 y), and the median PSA level was 18.0 ng/mL (range, 5.48-49.77 ng/mL). PCa was detected in 15 of 31 patients (48.4%), and 12 of 31 patients (38.7%) had clinically significant PCa (csPCa). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 68Ga-PSMA PET/CT in the diagnosis of csPCa were 100.0%, 68.4%, 66.7%, 100.0%, and 80.6%, respectively. The detection rate of PCa increased with the increase in miPSMA-ES. The detection rates of csPCa in the miPSMA-ES 0-1, 2, and 3 groups were 0%, 54.5%, and 85.7%, respectively. Semiquantitative analysis of 68Ga-PSMA PET/CT images showed that predictive models based on the SUVmax of prostate lesion, tumor-to-normal-prostate background SUVmax, and tumor-to-normal-liver background SUVmax could effectively predict csPCa; area under the curves were 0.930, 0.877, and 0.956, respectively. Conclusion: This study preliminarily confirmed that 68Ga-PSMA PET/CT imaging, combined with PET/ultrasound-guided prostate biopsy, can effectively detect csPCa. Prebiopsy 68Ga-PSMA PET/CT had predictive value for csPCa in the studied patient population.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu C, Liu T, Zhang Z, et al. 68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. J Nucl Med. 2020. PMID: 32034111. doi:10.2967/jnumed.119.235333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。